Fully automated quantification of hepatitis C virus (HCV) RNA in human plasma and human serum by the COBAS® AmpliPrep/COBAS® TaqMan® System

Journal of Clinical Virology

Volumn 38, Issue 4, 2007, Pages 326-333

  Sizmann, Dorothea ^a   Boeck, Claudia ^a   Boelter, Juergen ^a   Fischer, Daniela ^a   Miethke, Marion ^a   Nicolaus, Stefan ^a   Zadak, Markus ^a   Babiel, Reiner ^a  

^a ROCHE DIAGNOSTICS GMBH   (Germany)

Author keywords

Automated RNA extraction; HCV; Real time PCR; Therapy monitoring

Indexed keywords

ALPHA INTERFERON; NUCLEIC ACID; VIRUS RNA;

ARTICLE; AUTOMATION; CALIBRATION; DEVICE; DIAGNOSTIC ACCURACY; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; NONHUMAN; PLASMA; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RELIABILITY; RNA ANALYSIS; SENSITIVITY AND SPECIFICITY; SEROCONVERSION; SERUM; WORLD HEALTH ORGANIZATION;

ANALYSIS OF VARIANCE; HEPACIVIRUS; HEPATITIS C; HUMANS; PLASMA; POLYMERASE CHAIN REACTION; REPRODUCIBILITY OF RESULTS; RNA, VIRAL; SENSITIVITY AND SPECIFICITY; SERUM; VIRAL LOAD;

EID: 33947133809     PISSN: 13866532     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcv.2006.12.021     Document Type: Article

References (20)

1. Afdhal N.H. The natural history of hepatitis C. Semin Liver Dis 24 (2004) S3-S8
2. Berg T., Sarrazin C., Herrmann E., Hinrichsen H., Gerlach T., Zachoval R., et al. Prediction of treatment outcome in patients with chronic hepatitis C: significance of baseline parameters and viral dynamics during therapy. Hepatology 37 (2003) 600-609
3. Chevaliez S., and Pawlotsky J.-M. Hepatitis C virus serologic and virologic tests and clinical diagnosis of HCV-related liver disease. Int J Med Sci 3 (2006) 35-40
4. Davis G.L. Monitoring of viral levels during therapy of hepatitis C. Hepatology 36 (2002) S145-S151
5. ® HCV MONITOR test, version 2.0, an automated reverse transcription-PCR quantitative system for hepatitis C virus load determination. J Clin Microbiol 38 (2000) 2210-2214
6. Gourlain K., Soulier A., Pellegrin B., Bouvier-Alias M., Hezode C., Darthuy F., et al., DITTP Group. Dynamic range of hepatitis C virus RNA quantification with the Cobas Ampliprep-Cobas Amplicor HCV Monitor v2.0 assay. J Clin Microbiol 43 (2005) 1669-1673
7. Hoofnagle J.H. Course and outcome of hepatitis C. Hepatology 36 5 Suppl. 1 (2002) 21-29
8. Jungkind D. Automation of laboratory testing for infectious diseases using the polymerase chain reaction-out past, our present, our future. J Clin Virol 20 (2001) 1-6
9. Layden J.E., Layden T.J., Reddy K.R., Levy-Drummer R.S., Poulakos J., and Neumann A.U. First phase viral kinetic parameters as predictors of treatment response and their influence on the second phase viral decline. J Viral Hepat 9 (2002) 340-345
10. NIH, 2002. NIH consensus statement on management of hepatitis C: 2002. NIH Consens State Sci Statements, 19, 1-46.
11. Orito E., Mizokami M., Suzuki K., Ohba K., Ohno T., Mori M., et al. Loss of serum HCV RNA at week 4 of interferon-alpha therapy is associated with more favorable long-term response in patients with chronic hepatitis C. J Med Virol 46 (1995) 109-115
12. Puoti M., Zonaro A., Ravaggi A., Marin M.G., Castelnuovo F., and Cariani E. Hepatitis C virus RNA and antibody response in the clinical course of acute hepatitis C virus infection. Hepatology 16 (1992) 877-881
13. Ross R.S., Viazov S., Sarr S., Hoffmann S., Kramer A., and Roggendorf M. Quantitation of hepatitis C virus RNA by third generation branched DNA-based signal amplification assay. J Virol Meth 101 (2002) 159-168
14. Saldanha J., Lelie N., Heath A., and WHO Collaborative Study Group. Establishment of the first international standard for nucleic acid amplification technology (NAT) assays for HCV RNA. Vox Sang 76 (1999) 149-158
15. Saldanha J., Heath A., and Collaborative Study Group. Collaborative study to calibrate hepatitis C virus genotypes 2-6 against the HCV International Standard, 96/790 (genotype 1). Vox Sang 84 (2003) 20-27
16. Sarrazin C., Gartner B.C., Sizmann D., Babiel R., Mihm U., Hofmann W.P., et al. Comparison of conventional PCR with real-time PCR and branched DNA-based assays for hepatitis C virus RNA quantification and clinical significance for genotypes 1 to 5. J Clin Microbiol 44 (2006) 729-737
17. Simmonds P. Genetic diversity and evolution of hepatitis C virus-15 years on. J Gen Virol 85 (2004) 3173-3188
18. Wong J.B., Davis G.L., McHutchison J.G., Manns M.P., Albrecht J.K., and International Hepatitis Interventional Therapy Group. Economic and clinical effects of evaluating rapid viral response to peginterferon alfa-2b plus ribavirin for the initial treatment of chronic hepatitis C. Am J Gastroenterol 98 (2003) 2354-2362
19. Yamada G., Takatani M., Kishi F., Takahashi M., Doi T., Tsuji T., et al. Efficacy of interferon alfa therapy in chronic hepatitis C patients depends primarily on hepatitis C virus RNA level. Hepatology 22 (1995) 1351-1354
20. Zeuzem S., Lee J.H., Franke A., Ruster B., Prummer O., Herrmann G., et al. Quantification of the initial decline of serum hepatitis C virus RNA and response to interferon alfa. Hepatology 27 (1998) 1149-1156